drugset
drugset / Trial / NCT00549289

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)

NCT00549289 ↗

Phase 3 Completed Sirion Therapeutics, Inc.
NaSingle-groupOpen-label

Summary

The purpose of this phase III, open-label study is to determine the safety and tolerability of cyclosporine in the treatment of dry eye syndrome.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide — —

Indications

dry eye syndrome